Çѱ¹MSD(´ëÇ¥ Çöµ¿¿í)´Â Áö³ 16ÀÏ ¼¿ï ½¦¶óÅæ ±×·£µå ¿öÄ¿Èú ¾ÆƮȦ¿¡¼ Á¾ÇÕº´¿ø Àü¹®ÀÇ¿Í °³¿øÀÇ µî 140¿©¸íÀÌ Âü¼®ÇÑ °¡¿îµ¥ ‘ÄÚÀÚ ¹ß¸Å 15Áֳ⠱â³ä ½ÉÆ÷Áö¾ö’À» °³ÃÖÇß´Ù°í ¹àÇû´Ù.
À̹ø ½ÉÆ÷Áö¾öÀº ÄÚÀÚ ¹ß¸Å ÀÌÈÄ 15³â°£ ÁøÇàµÈ ´Ù¾çÇÑ ÀÓ»ó°ú ÃÖ½ÅÁö°ßÀ» ¾Æ¿ì¸£´Â ÀÚ¸®·Î ¸¶·ÃµÆ´Ù.
´ëÇÑ°íÇ÷¾ÐÇÐȸ À̻縦 ¸Ã°í ÀÖ´Â ¹Úâ±Ô ±³¼ö(°í·ÁÀÇ´ë ¼øȯ±â³»°ú)°¡ ÁÂÀåÀ¸·Î Âü¿©ÇßÀ¸¸ç Á¤ÀÎ°æ ±³¼ö(°æÈñÀÇ´ë ³»ºÐºñ³»°ú), ÀÌ»óÈ£ ±³¼ö(°æÈñÀÇ´ë ½ÅÀå³»°ú), °´öÈñ ±³¼ö(ÀÌÈ¿©´ë ½ÅÀå³»°ú), ÀÌÇØ¿µ ±³¼ö(¼¿ï´ëº´¿ø ¼øȯ±â³»°ú) µîÀÌ ¹ßÇ¥ÀÚ·Î ³ª¼¹´Ù.
À̳¯ ½ÉÆ÷Áö¿ò¿¡¼ ù ¹ø° ¹ßÇ¥¸¦ ¸ÃÀº Á¤ÀÎ°æ ±³¼ö´Â ‘Á¦2Çü ´ç´¢º´°ú °íÇ÷¾Ð ȯÀÚÀÇ ÀÓ»ó °ü¸®(Clinical Management of Patients with Type 2 Diabetes and Hypertension)’¶ó´Â ÁÖÁ¦·Î ¹ßÇ¥¸¦ À̲ø¾î ³ª°¬´Ù.
Á¤ ±³¼ö´Â “Áö³ 2002³â ¶õ¼Â(The Lancet)¿¡ º¸°íµÈ LIFE(Losartan Intervention For Endpoint reduction in hypertension study) Àӻ󿬱¸¿¡¼ ·ÎÀÚź±º°ú ¾ÆÅ׳î·Ñ(Atenolol)±ºÀ¸·Î ³ª´² ºÐ¼®À» ½Ç½ÃÇÑ °á°ú Ç÷¾Ð °ÇÏ È¿°ú´Â µÎ ±ºÀÌ ºñ½ÁÇßÁö¸¸ ·ÎÀÚź±º¿¡¼ »õ·Î¿î ´ç´¢È¯ÀÚÀÇ ¹ß»ýÀÌ 25% À¯ÀÇÇÏ°Ô ³·°Ô ³ªÅ¸³µ´Ù" °í ¹ßÇ¥Çß´Ù.
ÀÌ¾î µÎ ¹ø° ¹ßÇ¥¸¦ ¸ÃÀº ÀÌ»óÈ£ ±³¼ö´Â ‘´Ü¹é´¢ ½ÅÀåÁúȯ¿¡¼ ·ÎÀÚźÀÇ ¿ªÇÒ(Role of Losartan on Proteinuric Kidney Diseases)’À̶ó´Â ÁÖÁ¦·Î °¿¬À» ÁøÇà, RENAAL(Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) Àӻ󿬱¸ °á°ú¸¦ ÅëÇØ °íÇ÷¾Ð Ä¡·á¿ä¹ýÀ¸·Î¼, °íÇ÷¾ÐÀ» °¡Áø Á¦ 2Çü ´ç´¢º´ ȯÀÚÀÇ ½ÅÁúȯ¿¡¼ ·ÎÀÚźÀÇ È¿°ú¿¡ °üÇØ ¹ßÇ¥Çß´Ù.
ÀÌ ±³¼ö´Â “ARB Á¦Á¦´Â ´Ù¸¥ ¾àÁ¦µé¿¡ ºñÇØ Ç÷¾ÐÀ» È¿°úÀûÀ¸·Î ³·Ãß°í ´Ü¹é´¢¸¦ À¯ÀÇÇÏ°Ô °¨¼Ò½ÃÅ°´Â È¿°ú°¡ ÀÖ´Ù. ƯÈ÷ RENAAL ¿¬±¸¿¡¼ 252¸íÀÇ ¾Æ½Ã¾ÆÀÎÀ¸·Î ±¸¼ºµÈ ÇÏÀ§ Áý´Ü(sub-group)À» ºÐ¼®ÇÑ °á°ú¸¦ Èï¹Ì·Ó°Ô º¼ ¼ö Àִµ¥, ·ÎÀÚź(ARBÁ¦Á¦) Åõ¿©±º¿¡¼ ÀÏÂ÷ º¹ÇÕº¯¼öÀÎ Å©·¹¾ÆƼ´Ñ(creatinine) »ó½Â, ¸»±â ½ÅºÎÀü(ESRD), »ç¸Á¿¡ ´ëÇÑ À§ÇèÀÌ ´ëÁ¶±º ´ëºñ À¯ÀÇÇÏ°Ô °¨¼ÒÇß´Ù ”°í °Á¶Çß´Ù.
¼¼ ¹ø° ¿¬ÀÚ·Î ³ª¼± °´öÈñ ±³¼ö´Â '°íÇ÷¾Ð Ä¡·á¿¡ ÀÖ¾î ¿ä»êÀÇ ÀÇÀÇ'(The significance of Uric acid for hypertension treatment)¿¡ ´ëÇØ ¹ßÇ¥Çß´Ù.
° ±³¼ö´Â “¿ä»êÀº °íÇ÷¾Ð, ´ë»çÁõÈıº, ½ÅÀåÁúȯ µîÀÇ ¹ß»ý°ú ¿¬°ü¼ºÀÌ ÀÖ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù”¸ç “LIFE Study¿¡¼ ·ÎÀÚź°ú ´Ù¸¥ º£Å¸Â÷´ÜÁ¦¸¦ ºñ±³ÇØ ºÃÀ» ¶§ ·ÎÀÚź Åõ¿© ȯÀÚ¿¡¼ ¿ä»êÀÌ ´õ ³·°Ô ³ª¿Ô´Ù."¶ó°í ¹ßÇ¥Çß´Ù.
¸¶Áö¸·À¸·Î ÀÌÇØ¿µ ±³¼ö´Â ‘°íÇ÷¾Ð Ä¡·áÀÇ Çõ½Å (Innovation in hypertension management)’À̶ó´Â ÁÖÁ¦·Î ·ÎÀÚźÀÌ °®°í ÀÖ´Â È¿°ú¿¡ ´ëÇÑ ÃֽŠÁö°ßÀ» ¹ßÇ¥Çß´Ù.
Çѱ¹ MSD ±è»óÇ¥ »ó¹«´Â “´ëÇ¥ÀûÀÎ ARB °è¿ °íÇ÷¾ÐÄ¡·áÁ¦ÀÎ ÄÚÀÚ´Â Áö³ 15³â°£ ÀÔÁõµÈ Ç÷¾Ð °ÇÏ È¿°ú¿Í ¾ÈÀü¼ºÀº ¹°·Ð, ´Ü¹é´¢ °¨¼Ò µî ºÎ¼öÀûÀÎ È¿°ú°¡ ¼Ó¼Ó ¹àÇôÁö¸ç ¹ÏÀ» ¼ö ÀÖ´Â Ä¡·áÁ¦·Î ÀÚ¸®¸Å±èÇÏ°í ÀÖ´Ù. ÄÚÀÚ´Â 15³â ÈÄ¿¡µµ ¿À·£ Ä£±¸Ã³·³ ÇÔ²² °íÇ÷¾Ð Ä¡·áÀÇ ±æÀ» °É¾î°¡°Ú´Ù”°í ¸»Çß´Ù.
ÇÑÆí, ÄÚÀÚ(COZAAR, ¼ººÐ¸í: ·ÎÀÚź Ä®·ý)´Â °íÇ÷¾ÐÀÇ Ä¡·á¿Í °íÇ÷¾Ð Ä¡·á¿ä¹ýÀ¸·Î¼ °íÇ÷¾ÐÀ» °¡Áø Á¦2Çü ´ç´¢È¯ÀÚÀÇ ½ÅÁúȯ¿¡ ÀûÀÀÁõÀ» °®°í ÀÖ´Ù.
ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.